No Data
Peijia Medical Sees Up to 43% Jump in 2024 Revenue
PEIJIA-B (09996.HK) expected revenue for 2024 is approximately 0.61 billion yuan to -0.63 billion yuan, a year-on-year growth of about 38.3%-42.8%.
Gelonghui reported on February 10 that PEIJIA-B (09996.HK) announced that for the year ending December 31, 2024, the company's revenue is expected to be approximately 0.61 billion to 0.63 billion yuan, representing a year-on-year growth of about 38.3% to 42.8%. The strong revenue growth is mainly attributed to: (i) the continuous rapid growth of all neurointerventional product lines of the group; and (ii) the group's expanded market share in China's transcatheter aortic valve replacement ("TAVR") market. During the reporting period, the increase in surgical penetration rates, winning bids in volume-based procurement, and its comprehensive product pipeline and effective marketing contributed significantly.
Express News | Peijia Medical Sees FY Revenue Between RMB610.0 Mln and RMB630.0 Mln
AI hotspots continue to boost! Most Medical stocks in Hong Kong strengthen, with Micro-invasion Siasun Robot&Automation rising over 20%.
How does Sister Wood perceive this hot topic of AI Medical? What positive impacts will the emergence of DeepSeek bring to the medical field?
CITIC: Raised the Target Price of PEIJIA-B (09996) to 5 Hong Kong dollars, maintaining an "outperform industry" rating.
PEIJIA-B's rich product matrix helps respond to subsequent changes in the competitive landscape, and the company may continue to maintain its top position in the valve market.
Peijia Medical Completes First Compassionate Use Treatment of Aortic Valve Replacement Device
Peijia Medical Limited's (HKG:9996) 29% Share Price Plunge Could Signal Some Risk
